Attach to Form 990 or Form 990-EZ.
Go to
www.irs.gov/Form990 for instructions and the latest information.
| (i) Name of supported organization | (ii) EIN | (iii) Type of organization (described on lines 1- 10 above (see instructions)) | (iv) Is the organization listed in your governing document? | (v) Amount of monetary support (see instructions) | (vi) Amount of other support (see instructions) | |
|---|---|---|---|---|---|---|
| Yes | No | |||||
|
Total |
||||||
Calendar year
(or fiscal year beginning in)
![]() |
(a) 2020 | (b) 2021 | (c) 2022 | (d) 2023 | (e) 2024 | (f) Total | |
|---|---|---|---|---|---|---|---|
| 1 | Gifts, grants, contributions, and membership fees received. (Do not include any "unusual grant.") .. | 27,741,201 | 39,734,129 | 28,901,504 | 31,823,323 | 31,063,702 | 159,263,859 |
| 2 | Tax revenues levied for the organization's benefit and either paid to or expended on its behalf .... | ||||||
| 3 | The value of services or facilities furnished by a governmental unit to the organization without charge.. | ||||||
| 4 | Total. Add lines 1 through 3 | 27,741,201 | 39,734,129 | 28,901,504 | 31,823,323 | 31,063,702 | 159,263,859 |
| 5 | The portion of total contributions by each person (other than a governmental unit or publicly supported organization) included on line 1 that exceeds 2% of the amount shown on line 11, column (f) .. | 29,887,457 | |||||
| 6 | Public support. Subtract line 5 from line 4. | 129,376,402 | |||||
Calendar year
(or fiscal year beginning in)
![]() |
(a) 2020 | (b) 2021 | (c) 2022 | (d) 2023 | (e) 2024 | (f) Total | |
|---|---|---|---|---|---|---|---|
| 7 | Amounts from line 4.. | 27,741,201 | 39,734,129 | 28,901,504 | 31,823,323 | 31,063,702 | 159,263,859 |
| 8 | Gross income from interest, dividends, payments received on securities loans, rents, royalties and income from similar sources... | 4,394,213 | 4,142,169 | 3,519,873 | 5,031,481 | 4,698,648 | 21,786,384 |
| 9 | Net income from unrelated business activities, whether or not the business is regularly carried on.. | ||||||
| 10 | Other income. Do not include gain or loss from the sale of capital assets (Explain in Part VI.).. | 130,714 | 1,099,664 | 919,337 | 891,321 | 604,925 | 3,645,961 |
| 11 | Total support. Add lines 7 through 10 | 184,696,204 | |||||
Calendar year (or fiscal
year beginning in) ![]() |
(a) 2020 | (b) 2021 | (c) 2022 | (d) 2023 | (e) 2024 | (f) Total | |
|---|---|---|---|---|---|---|---|
| 1 | Gifts, grants, contributions, and membership fees received. (Do not include any "unusual grants.") . | ||||||
| 2 | Gross receipts from admissions, merchandise sold or services performed, or facilities furnished in any activity that is related to the organization's tax-exempt purpose | ||||||
| 3 | Gross receipts from activities that are not an unrelated trade or business under section 513 ..... | ||||||
| 4 | Tax revenues levied for the organization's benefit and either paid to or expended on its behalf... | ||||||
| 5 | The value of services or facilities furnished by a governmental unit to the organization without charge | ||||||
| 6 | Total. Add lines 1 through 5 | ||||||
| 7a | Amounts included on lines 1, 2, and 3 received from disqualified persons | ||||||
| b | Amounts included on lines 2 and 3 received from other than disqualified persons that exceed the greater of $5,000 or 1% of the amount on line 13 for the year. | ||||||
| c | Add lines 7a and 7b.. | ||||||
| 8 | Public support. (Subtract line 7c from line 6.) | ||||||
Calendar year
(or fiscal year beginning in)
![]() |
(a) 2020 | (b) 2021 | (c) 2022 | (d) 2023 | (e) 2024 | (f) Total | |
|---|---|---|---|---|---|---|---|
| 9 | Amounts from line 6... | ||||||
| 10a | Gross income from interest, dividends, payments received on securities loans, rents, royalties and income from similar sources.. | ||||||
| b | Unrelated business taxable income (less section 511 taxes) from businesses acquired after June 30, 1975. | ||||||
| c | Add lines 10a and 10b. | ||||||
| 11 | Net income from unrelated business activities not included on line 10b, whether or not the business is regularly carried on. | ||||||
| 12 | Other income. Do not include gain or loss from the sale of capital assets (Explain in Part VI.) .. | ||||||
| 13 | Total support. (Add lines 9, 10c, 11, and 12.).. | ||||||
| Section A - Adjusted Net Income | (A) Prior Year |
(B) Current Year (optional) |
||||
| 1 | Net short-term capital gain | 1 | ||||
| 2 | Recoveries of prior-year distributions | 2 | ||||
| 3 | Other gross income (see instructions) | 3 | ||||
| 4 | Add lines 1 through 3 | 4 | ||||
| 5 | Depreciation and depletion | 5 | ||||
| 6 | Portion of operating expenses paid or incurred for production or collection of gross income or for management, conservation, or maintenance of property held for production of income (see instructions) | 6 | ||||
| 7 | Other expenses (see instructions) | 7 | ||||
| 8 | Adjusted Net Income (subtract lines 5, 6 and 7 from line 4) | 8 | ||||
| Section B - Minimum Asset Amount | (A) Prior Year |
(B) Current Year (optional) |
||||
| 1 | Aggregate fair market value of all non-exempt-use assets (see instructions for short tax year or assets held for part of year): | 1 | ||||
| a | Average monthly value of securities | 1a | ||||
| b | Average monthly cash balances | 1b | ||||
| c | Fair market value of other non-exempt-use assets | 1c | ||||
| d | Total (add lines 1a, 1b, and 1c) | 1d | ||||
| e |
Discount claimed for blockage or other factors (explain in detail in Part VI): |
|||||
| 2 | Acquisition indebtedness applicable to non-exempt use assets | 2 | ||||
| 3 | Subtract line 2 from line 1d | 3 | ||||
| 4 | Cash deemed held for exempt use. Enter 0.015 of line 3 (for greater amount, see instructions). | 4 | ||||
| 5 | Net value of non-exempt-use assets (subtract line 4 from line 3) | 5 | ||||
| 6 | Multiply line 5 by 0.035 | 6 | ||||
| 7 | Recoveries of prior-year distributions | 7 | ||||
| 8 | Minimum Asset Amount (add line 7 to line 6) | 8 | ||||
| Section C - Distributable Amount | Current Year | |||||
| 1 | Adjusted net income for prior year (from Section A, line 8, Column A) | 1 | ||||
| 2 | Enter 85% of line 1 | 2 | ||||
| 3 | Minimum asset amount for prior year (from Section B, line 8, Column A) | 3 | ||||
| 4 | Enter greater of line 2 or line 3 | 4 | ||||
| 5 | Income tax imposed in prior year | 5 | ||||
| 6 | Distributable Amount. Subtract line 5 from line 4, unless subject to emergency temporary reduction (see instructions) | 6 | ||||
| Section D - Distributions | Current Year | |
|---|---|---|
| 1 Amounts paid to supported organizations to accomplish exempt purposes | 1 | |
|
2
Amounts paid to perform activity that directly furthers exempt purposes of supported organizations, in excess of income from activity |
2 | |
| 3 Administrative expenses paid to accomplish exempt purposes of supported organizations | 3 | |
| 4 Amounts paid to acquire exempt-use assets | 4 | |
| 5 Qualified set-aside amounts (prior IRS approval required - provide details in Part VI) | 5 | |
| 6 Other distributions (describe in Part VI). See instructions | 6 | |
| 7Total annual distributions. Add lines 1 through 6. | 7 | |
|
8
Distributions to attentive supported organizations to which the organization is responsive (provide details in Part VI). See instructions |
8 | |
| 9 Distributable amount for 2024 from Section C, line 6 | 9 | |
| 10 Line 8 amount divided by Line 9 amount | 10 | |
| Section E - Distribution Allocations (see instructions) |
(i) Excess Distributions |
(ii) Underdistributions Pre-2024 |
(iii) Distributable Amount for 2024 |
|
|---|---|---|---|---|
| 1 Distributable amount for 2024 from Section C, line 6 | ||||
|
2
Underdistributions, if any, for years prior to 2024 (reasonable cause required-- explain in Part VI).
See instructions. |
||||
| 3 Excess distributions carryover, if any, to 2024: | ||||
| a From 2019....... | ||||
| b From 2020....... | ||||
| c From 2021....... | ||||
| d From 2022....... | ||||
| e From 2023....... | ||||
| fTotal of lines 3a through e | ||||
| g Applied to underdistributions of prior years | ||||
| h Applied to 2024 distributable amount | ||||
|
i
Carryover from 2019 not applied (see instructions) |
||||
| j Remainder. Subtract lines 3g, 3h, and 3i from line 3f. | ||||
| 4Distributions for 2024 from Section D, line 7: | ||||
| $ | ||||
| a Applied to underdistributions of prior years | ||||
| b Applied to 2024 distributable amount | ||||
| c Remainder. Subtract lines 4a and 4b from line 4. | ||||
|
5
Remaining underdistributions for years prior to 2024, if any. Subtract lines 3g and 4a from line 2. If the amount is greater than zero, explain in Part VI. See instructions. |
||||
|
6
Remaining underdistributions for 2024. Subtract lines 3h and 4b from line 1. If the amount is greater than zero, explain in Part VI. See instructions. |
||||
|
7 Excess distributions carryover to 2025. Add lines 3j and 4c. |
||||
| 8 Breakdown of line 7: | ||||
| a Excess from 2020..... | ||||
| b Excess from 2021..... | ||||
| c Excess from 2022..... | ||||
| d Excess from 2023..... | ||||
| e Excess from 2024..... | ||||
| Facts And Circumstances Test |
|---|
| Return Reference | Explanation |
|---|---|
| SCHEDULE A, PART II, LINE 10, EXPLANATION OF OTHER INCOME: | FFB RD FUND SERVICE FEES - 2020 AMOUNT: $ 30,500. FUNDRAISING EVENTS - 2020 AMOUNT: $ 100,200. 2021 AMOUNT: $ 349,599. 2022 AMOUNT: $ 919,261. 2023 AMOUNT: $ 891,321. 2024 AMOUNT: $ 604,925. SETTLEMENT INCOME - 2021 AMOUNT: $ 750,000. MISCELLANEOUS - 2020 AMOUNT: $ 14. 2021 AMOUNT: $ 65. 2022 AMOUNT: $ 76. |
| Software ID: | |
| Software Version: |
| Return Reference | Explanation |
|---|---|
| PART I, LINE 1, ORGANIZATION'S MISSION OR SIGNIFICANT ACTIVITIES: | THE URGENT MISSION OF THE FOUNDATION FIGHTING BLINDNESS IS TO DRIVE THE RESEARCH THAT WILL PROVIDE PREVENTIONS, TREATMENTS AND CURES FOR PEOPLE AFFECTED BY RETINITIS PIGMENTOSA, AGE-RELATED MACULAR DEGENERATION, USHER SYNDROME AND THE ENTIRE SPECTRUM OF RETINAL DEGENERATIVE DISEASES. THE FOUNDATION IS A BEACON FOR THOSE AFFECTED BY THESE BLINDING DISEASES. |
| FORM 990, PART III, LINE 4A | RESEARCH: THE FOUNDATION FIGHTING BLINDNESS, INC. (THE FOUNDATION) FUNDED RESEARCHERS ARE ACHIEVING REMARKABLE SUCCESS IN DISCOVERING, TESTING, AND DELIVERING TO PATIENTS A WIDE RANGE OF PROMISING THERAPIES TO PREVENT, STOP THE PROGRESSION OF, AND CURE BLINDING DISEASES DUE TO RETINAL DEGENERATIVE DISEASES. THE FOUNDATION HAS ENCUMBRANCES OF OVER $36 MILLION, NOT INCLUDED ON OUR JUNE 30 FINANCIAL REPORT, FOR ACTIVE RESEARCH PROJECTS THAT HAVE FUTURE RESEARCH MILESTONES. OUR SCIENCE COMMITTEE'S SPENDING PLAN INCLUDES SPENDING AT AN AVERAGE OF $28 MILLION ANNUALLY TO SUPPORT FUTURE RESEARCH. AS OF THE END OF OUR FISCAL YEAR 2025, THE FOUNDATION'S RESEARCH GRANTS PROGRAM IS FUNDING 104 GRANTS BEING CONDUCTED BY MORE THAN 133 INVESTIGATORS AT 92 INSTITUTIONS, EYE HOSPITALS, AND UNIVERSITIES IN THE U.S. AND AROUND THE WORLD. A SAMPLING OF THE RESEARCH PROJECTS FUNDED ARE LISTED BELOW: "DEFINING THE UNDERLYING CAUSES OF RETINAL DEGENERATION IN CRB1 DISEASE." JEREMY KAY, DUKE UNIVERSITY DR. KAY AND HIS TEAM HYPOTHESIZE THAT LOSS OF CELL-CELL CONNECTIONS IN THE OUTER RETINA UNDERLIES RP-LIKE ASPECTS OF CRB1-ASSOCIATED DISEASE, WHILE LOSS OF JUNCTIONS BETWEEN EMBRYONIC PROGENITORS UNDERLIES LCA-LIKE ASPECTS. DR. KAY'S TEAM WILL USE MULTIPLE MODELS TO IDENTIFY PRIMARY SITE(S) OF DAMAGE CAUSED BY CRB1 DYSFUNCTION, AND EXPLORE STRATEGIES TO FIX THE DAMAGE. THEY WILL ALSO WORK TO DETERMINE WHETHER THESE CELLULAR FEATURES CAN BE IMAGED IN ANIMALS AND IN PATIENTS AND BE USED AS AN ENDPOINT IN FUTURE CLINICAL TRIALS. "DEVELOPMENT OF A NEW GENE THERAPY FOR AUTOSOMAL DOMINANT RETINITIS PIGMENTOSA" DENISE MONTELL, UNIVERSITY OF CALIFORNIA, SANTA BARBARA DR. MONTELL IS PIONEERING A GENE THERAPY APPROACH TO COMBAT RETINITIS PIGMENTOSA (RP), SPECIFICALLY THE AUTOSOMAL DOMINANT FORM CAUSED BY MISFOLDED RHODOPSIN PROTEIN. BY PROMOTING THE DEGRADATION OF MISFOLDED RHODOPSIN, THROUGH OVEREXPRESSION OF THE ZIP7 GENE, DR. MONTELL AIMS TO SLOW RETINAL DEGENERATION. ADDITIONALLY, OVEREXPRESSING THE ZIP7 GENEA ZINC TRANSPORTER PROTEINMAY RELIEVE CELLULAR STRESS AND PREVENT PHOTORECEPTOR CELL DEATH IN VARIOUS MODELS OF AUTOSOMAL DOMINANT RP. "CHARACTERIZATION AND MITIGATION OF AAV-INDUCED OCULAR INFLAMMATION" WILLIAM BELTRAN, UNIVERSITY OF PENNSYLVANIA DR. BELTRAN AND HIS TEAM ARE WORKING TO IMPROVE THE SAFETY OF GENE THERAPIES THAT USE VIRAL VECTORS TO DELIVER THE THERAPEUTIC GENE TO RETINAL CELLS. AS MORE IRD GENE THERAPIES MOVE FROM THE PRECLINICAL STAGE IN ANIMAL MODELS TO CLINICAL TRIALS, THERE IS AN INCREASING RECOGNITION OF THE NEED TO BETTER UNDERSTAND GENE THERAPY-ASSOCIATED UVEITIS (INFLAMMATION). THIS INFLAMMATORY RESPONSE CAN IMPEDE THE THERAPY'S PERFORMANCE AND CAN CAUSE RETINAL DAMAGE. |
| PART III, LINE 4B PROGRAM SERVICE ACCOMPLISHMENTS: | PUBLIC HEALTH EDUCATION: DURING FY25, THE FOUNDATION CONTINUED TO PROVIDE EDUCATION AND SUPPORT TO PEOPLE AFFECTED BY RETINAL DEGENERATIVE DISEASES. THE FOUNDATION ALSO FIELDS A TEAM OF PROFESSIONALS FOCUSED ON EDUCATING OPHTHALMOLOGISTS AND OPTOMETRISTS ON THE LATEST ADVANCEMENTS WITH THE FOUNDATION'S RESOURCES AND RESEARCH ON THE INHERITED RETINAL DISEASE SPACE. TO KEEP OUR CONSTITUENTS AND PROFESSIONALS INFORMED, THE FOUNDATION PUBLISHES EXTENSIVE CONTENT VIA THE WEBSITE AND SOCIAL MEDIA/EMAIL CHANNELS; DISTRIBUTES A NEWSLETTER ONLINE AND IN PRINT; PRODUCES AND SHARES EDUCATIONAL PODCASTS WITH LEADING EXPERTS IN THE SPACE; HOSTS VIRTUAL AND IN-PERSON EDUCATIONAL AND NETWORKING SEMINARS; AND HOLDS QUARTERLY INSIGHTS FORUM CALLS TO INFORM THE COMMUNITY ABOUT SCIENTIFIC PROGRESS. THE CONTENT INCLUDES THE LATEST DEVELOPMENTS IN RESEARCH AND CLINICAL TRIALS, AS WELL AS PERSONAL STORIES FROM MEMBERS OF OUR COMMUNITY. ADDITIONALLY, THE FOUNDATION HOSTS REGIONAL FORUM PRESENTATIONS THAT PROVIDE TIMELY CONTENT TO EYE CARE PROFESSIONALS. CHAPTERS BRING THE FOUNDATION'S MESSAGE AND MISSION TO LIFE. IN FY25, THE FOUNDATION SUPPORTED OVER 47 VOLUNTEER-LED CHAPTERS IN 23 STATES IN THE US AND ONE CHAPTER IN LONDON, UK. OUR CHAPTERS HOST VISION CONNECTION, AN ENRICHING AND SUPPORTIVE GATHERING FOR THE BLIND AND LOW-VISION COMMUNITY. EACH SESSION COVERS EDUCATIONAL PRESENTATIONS, COMMUNITY ENGAGEMENT, FUNDRAISING, AND INTERACTIVE Q&A SESSIONS. |
| PART III, LINE 4C PROGRAM SERVICE ACCOMPLISHMENTS: | MY RETINA TRACKER REGISTRY: THE FOUNDATION MAINTAINS A RESEARCH DATABASE OF PEOPLE AND FAMILIES AFFECTED BY RARE INHERITED RETINAL DEGENERATIVE DISEASES. THE REGISTRY IS DESIGNED TO SHARE DE-IDENTIFIED INFORMATION ABOUT PEOPLE WITH AN INHERITED RETINAL DISEASE WITHIN THE IRD RESEARCH AND CLINICAL COMMUNITIES TO HELP ACCELERATE THE DISCOVERY OF TREATMENTS AND CURES. DURING FISCAL YEAR 2025, APPROXIMATELY 8,000 ADDITIONAL MEMBERS WERE ADDED TO THE REGISTRY, BRINGING THE TOTAL NUMBER OF REGISTERED INDIVIDUALS TO APPROXIMATELY 43,000. |
| FORM 990, PART VI, SECTION A, LINE 2 | JONATHAN STEINBERG AND JOSHUA STEINBERG HAVE A FAMILY RELATIONSHIP. |
| FORM 990, PART VI, SECTION A, LINE 4 | IN MARCH 2025, FFB AMENDED ITS BYLAWS TO ALIGN WITH THE CURRENT STRUCTURE AND OPERATING PRACTICES. NOTABLE CHANGES INCLUDE A REDUCTION IN THE NUMBER OF STANDING COMMITTEES, THE CREATION OF THE EXECUTIVE VICE CHAIR POSITION, REMOVAL OF THE PRESIDENT AS AN ELECTED OFFICER, AND THE INTRODUCTION OF TERM LIMITS. |
| FORM 990, PART VI, SECTION A, LINE 6 | MEMBERS OF FFB ARE KNOWN AS NATIONAL TRUSTEES. THE QUALIFICATIONS AND ELIGIBILITY FOR MEMBERSHIP AND THE MANNER OF ADMISSION INTO MEMBERSHIP IS PRESCRIBED BY RESOLUTION OF THE BOARD OF DIRECTORS. THE NATIONAL TRUSTEES ARE ENTITLED TO VOTE ON ELECTION OF DIRECTORS. |
| FORM 990, PART VI, SECTION A, LINE 7A | DURING THE ANNUAL MEETING OF THE NATIONAL TRUSTEES, MEMBERS OF THE BOARD OF DIRECTORS ARE ELECTED. |
| FORM 990, PART VI, SECTION B, LINE 11B | DATA TO PREPARE THE FEDERAL FORM 990 IS PROVIDED TO OUR OUTSIDE ACCOUNTING FIRM FOR PREPARATION AND GUIDANCE. AFTER IT HAS BEEN COMPLETED, A DRAFT OF THE FEDERAL FORM 990 IS REVIEWED BY THE VP, FINANCE AND CHIEF OPERATING OFFICER. WITH THE COO'S APPROVAL, THE DRAFT FEDERAL FORM 990 IS THEN MADE AVAILABLE TO ALL BOARD MEMBERS. ALL BOARD MEMBERS ARE INVITED TO ATTEND A SPECIAL MEETING OF THE FINANCE COMMITTEE TO REVIEW THE FEDERAL FORM 990. A FINAL DRAFT IS MADE AVAILABLE TO ALL BOARD MEMBERS BEFORE FILING. |
| FORM 990, PART VI, SECTION B, LINE 12C | IN CONNECTION WITH ANY ACTUAL OR POSSIBLE CONFLICT OF INTEREST, AN INTERESTED PERSON (INCLUDING OFFICERS, DIRECTORS, AND KEY EMPLOYEES) MUST DISCLOSE, IN WRITING PRIOR TO ANY DISCUSSION OR VOTE UPON A PROPOSAL, THE EXISTENCE AND NATURE OF HIS OR HER PERSONAL INTEREST TO THE CHAIR OF THE BOARD AND CHAIR OF THE BOARD COMMITTEE CONSIDERING THE PROPOSED TRANSACTION OR ARRANGEMENT. AFTER DISCLOSURE OF THE FINANCIAL OR NON-FINANCIAL INTEREST AND ALL MATERIAL FACTS, THE INTERESTED PERSON SHALL LEAVE THE BOARD OR COMMITTEE MEETING WHILE THE FINANCIAL OR NON-FINANCIAL INTEREST IS DISCUSSED AND VOTED UPON. THE REMAINING BOARD SHALL DECIDE IF A CONFLICT OF INTEREST EXISTS, AND IF SO, WHETHER THERE IS A COMPELLING REASON TO RECOMMEND TO THE BOARD THAT THE CONFLICT OF INTEREST POLICY BE OVERRIDDEN. A QUORUM IS NEEDED FOR VOTING AND THE VOTE TO OVERRIDE SHALL BE BY MAJORITY AND DULY NOTED IN THE MINUTES. |
| FORM 990, PART VI, SECTION B, LINE 15 | THE EXECUTIVE COMMITTEE (COMPRISED OF INDEPENDENT PERSONS) AND THE BOARD OF DIRECTORS APPROVES THE COMPENSATION OF THE CHIEF EXECUTIVE OFFICER. THE EXECUTIVE COMMITTEE APPROVES THE COMPENSATION OF THE OTHER CHIEF OFFICERS. ON A ROUTINE BASIS, EXTERNAL DATA PROVIDED BY OUTSIDE EXPERT COMPENSATION CONSULTANTS IS USED TO MEASURE REASONABLENESS OF SALARIES TO THE MARKET PLACE AND RESULTS ARE COMMUNICATED BY OUTSIDE CONSULTANTS TO THE BOARD CHAIR/COMPENSATION COMMITTEE. DECISIONS MADE BY THE COMMITTEE ARE CONTEMPORANEOUSLY DOCUMENTED. |
| FORM 990, PART VI, SECTION C, LINE 19 | FFB'S FEDERAL FORM 990 AND CONSOLIDATED AUDITED FINANCIAL STATEMENTS ARE AVAILABLE AT WWW.FIGHTBLINDNESS.ORG. OTHER PUBLIC DOCUMENTS INCLUDING THE CONFLICT OF INTEREST POLICY ARE AVAILABLE UPON REQUEST THROUGH THE CONTACT INFORMATION DISCLOSED ON FFB'S WEB SITE. THESE DOCUMENTS ARE AVAILABLE FOR THE SAME PERIOD OF DISCLOSURE AS SET FORTH IN SECTION 6104(D). |
| FORM 990, PART VII, SECTION A: | FFB ACTS AS THE COMMON PAYMASTER FOR THE FOUNDATION FIGHTING BLINDNESS RETINAL DEGENERATION FUND, A RELATED ORGANIZATION. BOARD MEMBERS WERE NOT COMPENSATED FOR THEIR SERVICE ON THE BOARD, WITH THE EXCEPTION OF THE CHAIR OF THE RD FUND BOARD, WHO WAS COMPENSATED IN ACCORDANCE WITH THE RD FUND BOARD'S APPROVED COMPENSATION POLICY. |
| FORM 990, PART XI, LINE 9: | REFUND OF PREVIOUSLY EXPENDED GRANTS 11,693. |
| Software ID: | |
| Software Version: |